Structural insight into pH-induced conformational changes within the native human transthyretin tetramer.

Acidification of the transthyretin (TTR) tetramer facilitates dissociation and conformational changes in the protein, allowing alternatively folded monomers to self-assemble into insoluble amyloid fibers by a downhill polymerization mechanism in vitro. To investigate the influence of acidification on the quaternary and tertiary structures of TTR, crystal structures of wild-type human TTR at pH 4.0 and pH 3.5 have been determined to 1.7 A resolution. The acidic pH crystals are isomorphous to most of the previously reported TTR structures, containing two subunits in the asymmetric unit (the so-called A and B subunits) but forming a tetramer through crystallographic symmetry. The pH 4.0 crystal structure reveals that the native fold of the tetramer remains mostly undisturbed. In particular, subunit A of the TTR pH 4.0 structure is very similar to the wild-type TTR pH 7.4 structure with an r.m.s.d. of 0.38 A. In contrast, subunit B of the TTR pH 4.0 structure exhibits several significant changes. The EF-helix (residues 75-81) and the adjacent EF-loop (residues 82-90) show an r.m.s.d. greater than 2.0 A. The acidic residues within this region (Glu72, Asp74, Glu89, and Glu92) undergo significant conformational changes that instigate movement of the EF helix-loop region and make residues Lys70, Lys76, His88, and His90 orient their side chains toward these acidic residues. In particular, Glu89 undergoes a maximum deviation of 5.6 A, occupying Phe87's initial position in the wild-type TTR pH 7.4 structure, and points its side chain into a hydrophobic pocket of the neighboring subunit. In the pH 3.5 structure, the EF helix-loop region is completely disordered. These results demonstrate that acidic conditions increase the susceptibility of the EF helix-loop region of the TTR B subunit to undergo conformational changes and unfold, likely destabilizing the tetramer and identifying at least the initial conformational changes likely occurring within the tetramer that leads to the amyloidogenic monomer.

[1]  H. M. Petrassi,et al.  Screening transthyretin amyloid fibril inhibitors: characterization of novel multiprotein, multiligand complexes by mass spectrometry. , 2002, Structure.

[2]  T. Tokuda,et al.  Energetic Characteristics of the New Transthyretin Variant A25T May Explain Its Atypical Central Nervous System Pathology , 2003, Laboratory Investigation.

[3]  Joleen T White,et al.  D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? , 2003, Biochemistry.

[4]  L. Lally.  The CCP 4 Suite — Computer programs for protein crystallography , 1998 .

[5]  M. Benson,et al.  Biophysical analysis of normal transthyretin: Implications for fibril formation in senile systemic amyloidosis , 2001, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[6]  A Coda,et al.  Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. , 1995, Science.

[7]  M. Lei,et al.  Why is Leu55→Pro55 transthyretin variant the most amyloidogenic: Insights from molecular dynamics simulations of transthyretin monomers , 2003, Protein science : a publication of the Protein Society.

[8]  J. Kelly,et al.  Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. , 1995, Biochemistry.

[9]  Steven M. Johnson,et al.  Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. , 2005, Accounts of chemical research.

[10]  D. Foguel,et al.  The preaggregated state of an amyloidogenic protein: hydrostatic pressure converts native transthyretin into the amyloidogenic state. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Kelly,et al.  Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. , 1993, Biochemistry.

[12]  I. Wilson,et al.  Kinetic stabilization of the native state by protein engineering: implications for inhibition of transthyretin amyloidogenesis. , 2005, Journal of molecular biology.

[13]  Randy J Read,et al.  Electronic Reprint Biological Crystallography Likelihood-enhanced Fast Rotation Functions Biological Crystallography Likelihood-enhanced Fast Rotation Functions , 2003 .

[14]  Maria João,et al.  Transthyretin mutations in health and disease , 1995, Human mutation.

[15]  C R Kissinger,et al.  Rapid automated molecular replacement by evolutionary search. , 1999, Acta crystallographica. Section D, Biological crystallography.

[16]  X-ray crystallographic studies of two transthyretin variants: further insights into amyloidogenesis. , 2005, Acta crystallographica. Section D, Biological crystallography.

[17]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[18]  J. Kelly,et al.  The pathway by which the tetrameric protein transthyretin dissociates. , 2005, Biochemistry.

[19]  D. Small,et al.  Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. , 2007, The FEBS journal.

[20]  J. Hamilton,et al.  Structural changes in transthyretin produced by the Ile 84 Ser mutation which result in decreased affinity for retinol-binding protein , 1996 .

[21]  J. Buxbaum,et al.  The genetics of the amyloidoses. , 2000, Annual review of medicine.

[22]  S. Ikeda.  Clinical Picture and Outcome of Transthyretin-Related Familial Amyloid Polyneuropathy (FAP) in Japanese Patients , 2002, Clinical chemistry and laboratory medicine.

[23]  E A Merritt,et al.  Raster3D Version 2.0. A program for photorealistic molecular graphics. , 1994, Acta crystallographica. Section D, Biological crystallography.

[24]  J. Kelly,et al.  Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: implications for transthyretin amyloidosis. , 2005, Biochemistry.

[25]  J. Liepnieks,et al.  A transthyretin mutation (Tyr78Phe) associated with peripheral neuropathy, carpal tunnel syndrome and skin amyloidosis , 2003, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[26]  J. Hamilton,et al.  Transthyretin: a review from a structural perspective , 2001, Cellular and Molecular Life Sciences CMLS.

[27]  A. Olofsson,et al.  A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. , 2000, Journal of molecular biology.

[28]  J. Kelly,et al.  The Biological and Chemical Basis for Tissue-Selective Amyloid Disease , 2005, Cell.

[29]  A. Wojtczak,et al.  HUMAN TRANSTHYRETIN COMPLEXED WITH THYROXINE , 1996 .

[30]  M. Benson.  Leptomeningeal amyloid and variant transthyretins. , 1996, The American journal of pathology.

[31]  C. Pace,et al.  pK values of the ionizable groups of proteins , 2006, Protein science : a publication of the Protein Society.

[32]  Joleen T White,et al.  Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. , 2004, Biochemistry.

[33]  D E McRee,et al.  XtalView/Xfit--A versatile program for manipulating atomic coordinates and electron density. , 1999, Journal of structural biology.

[34]  Scott A. Peterson,et al.  Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. , 1997, Advances in protein chemistry.

[35]  D. Wemmer,et al.  A glimpse of a possible amyloidogenic intermediate of transthyretin , 2000, Nature Structural Biology.

[36]  H. M. Petrassi,et al.  An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. , 2001, Biochemistry.

[37]  W. Kabsch.  A solution for the best rotation to relate two sets of vectors , 1976 .

[38]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[39]  J. Kelly,et al.  Hydration and packing are crucial to amyloidogenesis as revealed by pressure studies on transthyretin variants that either protect or worsen amyloid disease. , 2003, Journal of molecular biology.

[40]  Bernhard Rupp,et al.  Effective electron-density map improvement and structure validation on a Linux multi-CPU web cluster: The TB Structural Genomics Consortium Bias Removal Web Service. , 2003, Acta crystallographica. Section D, Biological crystallography.

[41]  Steven M. Johnson,et al.  Kinetic stabilization of an oligomeric protein by a single ligand binding event. , 2005, Journal of the American Chemical Society.

[42]  Scott A. Peterson,et al.  Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. Newcomer,et al.  The structure of human retinol-binding protein (RBP) with its carrier protein transthyretin reveals an interaction with the carboxy terminus of RBP. , 1999, Biochemistry.

[44]  J. Sacchettini,et al.  Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization. , 2003, Journal of the American Chemical Society.

[45]  M. Saraiva,et al.  Biochemical marker in familial amyloidotic polyneuropathy, Portuguese type. Family studies on the transthyretin (prealbumin)-methionine-30 variant. , 1985, The Journal of clinical investigation.

[46]  C. Wurth,et al.  The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. , 1999, Biochemistry.

[47]  K. Sletten,et al.  Fibril in senile systemic amyloidosis is derived from normal transthyretin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Kelly,et al.  Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. , 1992, Biochemistry.

[49]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[50]  J. Kelly,et al.  The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. , 1996, Biochemistry.

[51]  M. Saraiva,et al.  Search for intermediate structures in transthyretin fibrillogenesis: soluble tetrameric Tyr78Phe TTR expresses a specific epitope present only in amyloid fibrils. , 2000, Journal of molecular biology.

[52]  J. Buxbaum,et al.  Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. , 1997, The New England journal of medicine.

[53]  L. Cendron,et al.  Acidic pH-induced conformational changes in amyloidogenic mutant transthyretin. , 2007, Journal of molecular biology.

[54]  J. Kelly,et al.  Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation. , 1998, Biochemistry.

[55]  D. Craik,et al.  1H-NMR structural studies of a cystine-linked peptide containing residues 71-93 of transthyretin and effects of a Ser84 substitution implicated in familial amyloidotic polyneuropathy. , 1999, European journal of biochemistry.

[56]  J. Kelly,et al.  Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[57]  J. Kelly,et al.  Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics , 2003, Science.

[58]  J. Hamilton,et al.  The x-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30-->Met variant to 1.7-A resolution. , 1993, The Journal of biological chemistry.